Follow Adlai Nortye Group Ltd.. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.
5 Stories in coverage 0 Programs 11 recruiting Registered trial 10-Q Nov 13 Latest SEC filing Oct 28 Latest story
Timeline 5 Pipeline 0 Trials 1
All5 Regulatory1 Trials and readouts2 Filings and people2
Details
Headquarters Singapore Incorporated Delaware Industry Pharmaceutical Preparations Formerly Adlai Nortye Ltd. (to 2026) Also known as Adlai Nortye Ltd., ANL How the company describes itself Adlai Nortye develops cancer therapies including the oral pan-RAS inhibitor AN9025, the CEACAM5-targeting antibody-drug conjugate AN4035, and AN8025, a PD-1/L1 pathway fusion protein. The clinical-stage company is based globally. source